Novartis and Samsung Biologics expand biologics manufacturing partnership

Samsung Biologics disclosed it is significantly expanding a 2022 pact with Novartis for biologics manufacturing. The expansion is valued at $309 million over five years.

“Samsung Biologics disclosed Monday that it’s significantly expanding a 2022 pact with Novartis to help with the Swiss company’s biologics manufacturing.”endpts.com

• 1 source
• endpts.comNo­var­tis and Sam­sung ink five-year, $309M ex­pan­sion to bi­o­log­ics man­u­fac­tur­ing part­ner­shipJul 10, 2023

Summarized from public sources; check the original articles before acting on it.